1/1,11th Cross st, Shastri Nagar, Adyar, Chennai, Tamil Nadu 600020.
The healthcare world has been going through many changes in the past few years, with digitalisation growing tremendously. There have been better treatment opportunities through self-health monitoring facilities using smart medical devices and cloud-based data platforms. Under digital therapeutics solution (DTx), innovative tech software is developed to help patients cope with medical illnesses. Several clinics in Chennai and other big cities use digital therapeutics to cure millions of people everyday.
A digital therapeutics solution is a high-quality, clinically proven software system to prevent, manage and treat patients with medical ailments. They use AI, MD and NLP to access patient data. Digital therapeutics offer behaviour recommendations, medicine intake alerts, health-related tips and exercise plans. Thus, it is unique and stands out from other wellness applications and covers a wide array of diseases like obesity, type 2 diabetes, depression, ADHD, anxiety, congestive heart failure, etc. Digital therapeutics functions as:
The DTx products must follow certain principles, namely,
Digital therapeutics has promising advantages for patients, physicians, distributors, payers, stakeholders and care providers. Being a relatively new concept, let us discuss how they are benefitted.
Patients use digital therapeutics through software applications that can:
There are a few steps to follow while developing DTx products. The four major processes while inventing any digital therapeutics solution are researching, deciding on a strategy, creating a design and developing them.
The research process follows two potential areas. They are:
Companies have to decide on how they are going to create the product. The DTx software may perform in-house or in-licensing product developments. Large companies follow in-house developments in places like Chennai with sufficient financial resources. They identify and hire professionals for the entire process. The professionals include clinicians, design experts, software engineers, data scientists, product managers and regulation experts. The process involves many cross-functional collaborations, which happen throughout the entire product design cycle. In-licensing development is used by companies that do not want to hire an additional workforce but wish to increase and expand their DTx portfolio. In such scenarios, instead of starting from the ground level, these companies can invest in ongoing research that any third party performs. This shortcut is beneficial for labs or centres with a financial crisis to complete their study and penetrate their digital therapeutics solution into the market using patient-centric software.
Development is the most crucial stage for any DTx product. There are a few phases here, irrespective of the type of business strategy used to create the product. The first is the pre-clinical phase, which involves developing therapeutic interventions that are undergoing clinical trials or existing in scientific literature. This will get converted into digital records. The next stage is running the digital therapeutics solution or software trial version. It will be possible to evaluate the impact of the therapy in this step with an opportunity to determine its developments in future. The initial test will assess the product usability and the solution's accessibility to patients. Following this test, a pilot clinical study will be performed on a narrow group of patients, and specialists will control the usage conditions. This clinical study will decide whether the DTx product will enter the complete developmental stage. Only when the pilot stage is a success will the solution go through other clinical trials to gain regulatory validation from authorities, insurance companies, and healthcare providers. If not, it will be shut down then and there.
Many ailments and diseases can be cured with digital therapeutics! A combination of sensory-stimulating VR with traditional cognitive behavioural therapy is used to treat ADHD. This is the most recent effective and successful digital therapeutics solution that treats kids between 7 and 12 years. It sends low electric pulses to the brain to improve their behavioural adaption and emotions. Thus, medical professionals will keep pursuing the development of digital therapeutics in better ways to provide remarkable healthcare. We can also expect more treatments and remedies for other specific disorders in the near future.